{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:55:18Z","timestamp":1782946518840,"version":"3.54.5"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-07058-7","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:19:03Z","timestamp":1759238343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Yasunari","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Mizusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Nishina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Katanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihito","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiya","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Sugimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Terashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"7058_CR1","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. & Brandi, G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat. Res. Commun. 27, 100354 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"7058_CR2","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology; Biliary Tract Cancers, version 1 [cited 2025 Mar 20]. NCCN; 2025."},{"key":"7058_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. & Brandi, G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: Reflections on a standard of care. Expert. Rev. Gastroenterol. Hepatol. 15, 483\u2013485 (2021).","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"7058_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","volume":"401","author":"K Nakachi","year":"2023","unstructured":"Nakachi, K. et al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): A multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401, 195\u2013203 (2023).","journal-title":"Lancet"},{"key":"7058_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jhbp.314","volume":"23","author":"S Ishihara","year":"2016","unstructured":"Ishihara, S. et al. Biliary tract cancer registry in Japan from 2008 to 2013. J. Hepato-Bil. Pancreat. Sci. 23, 149\u2013157 (2016).","journal-title":"J. Hepato-Bil. Pancreat. Sci."},{"key":"7058_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka, T. et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br. J. Cancer. 103, 469\u2013474 (2010).","journal-title":"Br. J. Cancer."},{"key":"7058_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281 (2010).","journal-title":"N. Engl. J. Med."},{"key":"7058_CR8","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane, C. et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950\u20131958 (2019).","journal-title":"Ann. Oncol."},{"key":"7058_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka, T. et al. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA). J. Hepato-Bil. Pancreat. Sci. 30, 102\u2013110 (2023).","journal-title":"J. Hepato-Bil. Pancreat. Sci."},{"key":"7058_CR10","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"7058_CR11","doi-asserted-by":"crossref","unstructured":"Oh, D. Y. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","DOI":"10.1056\/EVIDoa2200015"},{"key":"7058_CR12","doi-asserted-by":"crossref","unstructured":"Sahin, T. K. et al. Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: A systematic review and meta-analysis. Cancers (Basel).\u00a016, 3689 (2024).","DOI":"10.3390\/cancers16213689"},{"key":"7058_CR13","doi-asserted-by":"crossref","unstructured":"Sahin, T. K. et al. Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: A systematic review and meta-analysis. Cancers (Basel) 16, 1835 (2024).","DOI":"10.3390\/cancers16101835"},{"key":"7058_CR14","doi-asserted-by":"publisher","first-page":"8285","DOI":"10.1074\/jbc.271.14.8285","volume":"271","author":"D Mu","year":"1996","unstructured":"Mu, D., Hsu, D. S. & Sancar, A. Reaction mechanism of human DNA repair excision nuclease. J. Biol. Chem. 271, 8285\u20138294 (1996).","journal-title":"J. Biol. Chem."},{"key":"7058_CR15","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1126\/science.7801120","volume":"266","author":"A Sancar","year":"1994","unstructured":"Sancar, A. Mechanisms of DNA excision repair. Science 266, 1954\u20131956 (1994).","journal-title":"Science"},{"key":"7058_CR16","doi-asserted-by":"publisher","first-page":"10004","DOI":"10.1021\/bi960453+","volume":"35","author":"DB Zamble","year":"1996","unstructured":"Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A. & Lippard, S. J. Repair of cisplatin\u2014DNA adducts by the mammalian excision nuclease. Biochemistry 35, 10004\u201310013 (1996).","journal-title":"Biochemistry"},{"key":"7058_CR17","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie, G. D., Sommadossi, J. P., Cross, D. S., Huster, W. J. & Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 47, 2203\u20132206 (1987).","journal-title":"Cancer Res."},{"key":"7058_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0959-8049(97)00366-3","volume":"34","author":"JA van Laar","year":"1998","unstructured":"van Laar, J. A., Rustum, Y. M., Ackland, S. P., van Groeningen, C. J. & Peters, G. J. Comparison of 5-fluoro-2\u2032-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer. 34, 296\u2013306 (1998).","journal-title":"Eur. J. Cancer."},{"key":"7058_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1248\/cpb.31.175","volume":"31","author":"A Kono","year":"1983","unstructured":"Kono, A. et al. Activation of 5\u2032-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem. Pharm. Bull. (Tokyo) 31, 175\u2013178 (1983).","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"7058_CR20","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/bjc.2013.576","volume":"109","author":"JE Bauman","year":"2013","unstructured":"Bauman, J. E. et al. ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br. J. Cancer 109, 2096\u20132105 (2013).","journal-title":"Br. J. Cancer"},{"key":"7058_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/annonc\/mdl435","volume":"18","author":"J Bellmunt","year":"2007","unstructured":"Bellmunt, J. et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 18, 522\u2013528 (2007).","journal-title":"Ann. Oncol."},{"key":"7058_CR22","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00280-011-1558-3","volume":"68","author":"IG Hwang","year":"2011","unstructured":"Hwang, I. G. et al. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients. Cancer Chemother. Pharmacol. 68, 935\u2013944 (2011).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"7058_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","volume":"16","author":"R Metzger","year":"1998","unstructured":"Metzger, R. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16, 309\u2013316 (1998).","journal-title":"J. Clin. Oncol."},{"key":"7058_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1056\/NEJMoa060570","volume":"355","author":"KA Olaussen","year":"2006","unstructured":"Olaussen, K. A. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983\u2013991 (2006).","journal-title":"N. Engl. J. Med."},{"key":"7058_CR25","doi-asserted-by":"publisher","first-page":"5808","DOI":"10.1200\/JCO.2009.21.9766","volume":"27","author":"C Reynolds","year":"2009","unstructured":"Reynolds, C. et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J. Clin. Oncol. 27, 5808\u20135815 (2009).","journal-title":"J. Clin. Oncol."},{"key":"7058_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0222140","volume":"14","author":"M Suksawat","year":"2019","unstructured":"Suksawat, M. et al. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. PLoS ONE 14, e0222140 (2019).","journal-title":"PLoS ONE"},{"key":"7058_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2407-12-187","volume":"12","author":"JM Sun","year":"2012","unstructured":"Sun, J. M. et al. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer 12, 187 (2012).","journal-title":"BMC Cancer"},{"key":"7058_CR28","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1158\/1078-0432.CCR-04-0247","volume":"10","author":"W Zhou","year":"2004","unstructured":"Zhou, W. et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10, 4939\u20134943 (2004).","journal-title":"Clin. Cancer Res."},{"key":"7058_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","volume":"368","author":"L Friboulet","year":"2013","unstructured":"Friboulet, L. et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N. Engl. J. Med. 368, 1101\u20131110 (2013).","journal-title":"N. Engl. J. Med."},{"key":"7058_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.dnarep.2018.02.002","volume":"64","author":"MS Kuo","year":"2018","unstructured":"Kuo, M. S. et al. A novel antibody-based approach to detect the functional ERCC1-202 isoform. DNA Repair 64, 34\u201344 (2018).","journal-title":"DNA Repair"},{"key":"7058_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/jclinpath-2015-203397","volume":"69","author":"M Mian","year":"2016","unstructured":"Mian, M. et al. Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers. J. Clin. Pathol. 69, 695\u2013701 (2016).","journal-title":"J. Clin. Pathol."},{"key":"7058_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4143\/crt.2013.45.1.63","volume":"45","author":"KW Park","year":"2013","unstructured":"Park, K. W. et al. ERCC1 can be a prognostic factor in hilar cholangiocarcinoma and extrahepatic bile duct cancer, but not in intrahepatic cholangiocarcinoma. Cancer Res. Treat. 45, 63\u201369 (2013).","journal-title":"Cancer Res. Treat."},{"key":"7058_CR33","doi-asserted-by":"crossref","unstructured":"da Costa Miranda, V. et al. ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: Prognostic and predictive roles. J. Gastrointest. Cancer 45, 80\u201386 (2014).","DOI":"10.1007\/s12029-013-9568-5"},{"key":"7058_CR34","doi-asserted-by":"publisher","first-page":"S627","DOI":"10.1245\/s10434-014-3726-2","volume":"21","author":"S Uemura","year":"2014","unstructured":"Uemura, S., Kuramochi, H., Higuchi, R., Nakajima, G. & Yamamoto, M. ERCC1 mRNA expression as a postoperative prognostic marker in extrahepatic bile duct cancer. Ann. Surg. Oncol. 21, S627\u2013S633 (2014).","journal-title":"Ann. Surg. Oncol."},{"key":"7058_CR35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/cncr.27739","volume":"119","author":"SB Fisher","year":"2013","unstructured":"Fisher, S. B. et al. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. Cancer 119, 454\u2013462 (2013).","journal-title":"Cancer"},{"key":"7058_CR36","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1186\/1471-2407-10-564","volume":"10","author":"HS Won","year":"2010","unstructured":"Won, H. S. et al. Comparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer. BMC Cancer 10, 564 (2010).","journal-title":"BMC Cancer"},{"key":"7058_CR37","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1038\/bjc.2013.127","volume":"108","author":"M Tiseo","year":"2013","unstructured":"Tiseo, M. et al. ERCC1\/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br. J. Cancer 108, 1695\u20131703 (2013).","journal-title":"Br. J. Cancer"},{"key":"7058_CR38","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/ijc.24772","volume":"126","author":"HY Chen","year":"2010","unstructured":"Chen, H. Y., Shao, C. J., Chen, F. R., Kwan, A. L. & Chen, Z. P. Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int. J. Cancer 126, 1944\u20131954 (2010).","journal-title":"Int. J. Cancer"},{"key":"7058_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1126\/science.1083557","volume":"300","author":"A Eden","year":"2003","unstructured":"Eden, A., Gaudet, F., Waghmare, A. & Jaenisch, R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455 (2003).","journal-title":"Science"},{"key":"7058_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1126\/science.1083558","volume":"300","author":"F Gaudet","year":"2003","unstructured":"Gaudet, F. et al. Induction of tumors in mice by genomic hypomethylation. Science 300, 489\u2013492 (2003).","journal-title":"Science"},{"key":"7058_CR41","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1103","volume":"3","author":"E Greenwood","year":"2003","unstructured":"Greenwood, E. Less is more. Nat. Rev. Cancer 3, 392 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"7058_CR42","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1093\/annonc\/mdt238","volume":"24","author":"Y Yamada","year":"2013","unstructured":"Yamada, Y. et al. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group trial JCOG9912. Ann. Oncol. 24, 2560\u20132565 (2013).","journal-title":"Ann. Oncol."},{"key":"7058_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/em.1073","volume":"38","author":"MD Wilson","year":"2001","unstructured":"Wilson, M. D., Ruttan, C. C., Koop, B. F. & Glickman, B. W. ERCC1: a comparative genomic perspective. Environ. Mol. Mutagen 38, 209\u2013215 (2001).","journal-title":"Environ. Mol. Mutagen"},{"key":"7058_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0016-5085(99)70558-5","volume":"117","author":"JM Carethers","year":"1999","unstructured":"Carethers, J. M. et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117, 123\u2013131 (1999).","journal-title":"Gastroenterology"},{"key":"7058_CR45","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1158\/1078-0432.656.11.2","volume":"11","author":"C An","year":"2005","unstructured":"An, C. et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin. Cancer Res. 11, 656\u2013663 (2005).","journal-title":"Clin. Cancer Res."},{"key":"7058_CR46","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1038\/bjc.2012.502","volume":"107","author":"H Baba","year":"2012","unstructured":"Baba, H. et al. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. Br. J. Cancer 107, 1950\u20131955 (2012).","journal-title":"Br. J. Cancer"},{"key":"7058_CR47","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-11-0790","volume":"17","author":"L Friboulet","year":"2011","unstructured":"Friboulet, L. et al. Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin. Cancer Res. 17, 5562\u20135572 (2011).","journal-title":"Clin. Cancer Res."},{"key":"7058_CR48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.yexmp.2017.01.006","volume":"102","author":"AB Kassem","year":"2017","unstructured":"Kassem, A. B. et al. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt. Exp. Mol. Pathol. 102, 78\u201385 (2017).","journal-title":"Exp. Mol. Pathol."},{"key":"7058_CR49","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","volume":"28","author":"L Righi","year":"2010","unstructured":"Righi, L. et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J. Clin. Oncol. 28, 1534\u20131539 (2010).","journal-title":"J. Clin. Oncol."},{"key":"7058_CR50","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.lungcan.2011.08.016","volume":"75","author":"A Vilmar","year":"2012","unstructured":"Vilmar, A., Garcia-Foncillas, J., Huarriz, M., Santoni-Rugiu, E. & Sorensen, J. B. RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 75, 306\u2013312 (2012).","journal-title":"Lung Cancer"},{"key":"7058_CR51","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s12032-010-9590-4","volume":"28","author":"IS Choi","year":"2011","unstructured":"Choi, I. S. et al. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med. Oncol. 28, 991\u2013998 (2011).","journal-title":"Med. Oncol."},{"key":"7058_CR52","first-page":"2763","volume":"31","author":"K Kaira","year":"2011","unstructured":"Kaira, K. et al. Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. Anticancer Res. 31, 2763\u20132771 (2011).","journal-title":"Anticancer Res."},{"key":"7058_CR53","first-page":"645","volume":"30","author":"M Karlberg","year":"2010","unstructured":"Karlberg, M. et al. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer. Anticancer Res. 30, 645\u2013651 (2010).","journal-title":"Anticancer Res."},{"key":"7058_CR54","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1002\/jso.21879","volume":"103","author":"Y Kato","year":"2011","unstructured":"Kato, Y. et al. Impact of intratumoral thymidylate synthase expression on prognosis after surgical resection for ampullary carcinoma. J. Surg. Oncol. 103, 663\u2013668 (2011).","journal-title":"J. Surg. Oncol."},{"key":"7058_CR55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/jso.21955","volume":"104","author":"N Kondo","year":"2011","unstructured":"Kondo, N. et al. Prognostic impact of dihydropyrimidine dehydrogenase expression on pancreatic adenocarcinoma patients treated with S-1-based adjuvant chemotherapy after surgical resection. J. Surg. Oncol. 104, 146\u2013154 (2011).","journal-title":"J. Surg. Oncol."},{"key":"7058_CR56","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1872-034X.2010.00722.x","volume":"41","author":"M Nishi","year":"2011","unstructured":"Nishi, M. et al. Role of dihydropyrimidine dehydrogenase and thymidylate synthase expression in immunohistochemistry of intrahepatic cholangiocarcinoma. Hepatol. Res. 41, 64\u201370 (2011).","journal-title":"Hepatol. Res."},{"key":"7058_CR57","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.3892\/ol.2014.2574","volume":"8","author":"M Ogawa","year":"2014","unstructured":"Ogawa, M. et al. Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer. Oncol. Lett. 8, 2463\u20132468 (2014).","journal-title":"Oncol. Lett."},{"key":"7058_CR58","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s10120-014-0413-8","volume":"18","author":"M Sasako","year":"2015","unstructured":"Sasako, M. et al. Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II\/III gastric cancer. Gastric Cancer 18, 538\u2013548 (2015).","journal-title":"Gastric Cancer"},{"key":"7058_CR59","first-page":"2755","volume":"34","author":"T Okimoto","year":"2014","unstructured":"Okimoto, T. et al. Immunohistochemical comparison of biomarker expression in biopsy and surgical specimens of non-small cell lung cancer. Anticancer Res. 34, 2755\u20132761 (2014).","journal-title":"Anticancer Res."},{"key":"7058_CR60","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/annonc\/mdm072","volume":"18","author":"L Taillade","year":"2007","unstructured":"Taillade, L. et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann. Oncol. 18, 1043\u20131050 (2007).","journal-title":"Ann. Oncol."},{"key":"7058_CR61","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07058-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07058-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07058-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:22:57Z","timestamp":1759242177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-07058-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7058"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-07058-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasunari Sakamoto, Chigusa Morizane, Takuji Okusaka, Nobuyoshi Hiraoka, Tomoki Shirota, Satoshi Kobayashi, Masato Ozaka, Naohiro Okano, Hironori Yamaguchi, Nobumasa Mizuno, Tomohiro Nishina, Akio Katanuma, Yasushi Kojima, Kunihito Gotoh, Keiya Okamura, Yasuyuki Kawamoto, Kazuya Sugimori, Takeshi Terashima, Rie Sugimoto, Hirofumi Shirakawa have no conflicts of interest to disclose. Junki Mizusawa, received honoraria from Taiho pharmaceutical Co., Ltd., Chugai pharmaceutical Co., Ltd., outside the submitted work; his spouse is an employee of Pfizer. Makoto Ueno received research grants from Taiho Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. Masafumi Ikeda received research grants from AstraZeneca K.K., Eisai Co., Ltd., Eli Lilly Japan K.K., J-Pharma Co., Ltd., Merck BioPharma Co., Ltd., and Ono Pharmaceutical Co., Ltd. Hiroshi Imaoka received research grant from Ono Pharmaceutical Co., Ltd., Nihon Servier Co., Ltd., Novartis Pharma K.K., Boehringer Ingelheim Co., Ltd.; honoraria from Nihon Servier Co., Ltd, Yakult Pharmaceutical Industry Co., Ltd., Boston Scientific Corporation, Kaneka Medix Corporation, Medico\u2019s Hirata Inc., SB-Kawasumi Laboratories Inc., AstraZeneca K.K., Novartis Pharma K.K.; payment for expert testimony from Kaneka Medix Corporation; participated on Advisory Board of Nihon Servier Co., Ltd. Junji Furuse received honoraria from Taiho Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33862"}}